Beyond HRD Status: Unraveling Genetic Variants Impacting PARP Inhibitor Sensitivity in Advanced Ovarian Cancer.
Kjeldsen MK, Jørgensen M, Grønseth DSB, Schønemann-Lund M, Nyvang GB, Haslund CA, Knudsen AO, Motavaf AK, Malander S, Anttila M, Lindahl G, Mäenpää J, Dimoula M, Werner TL, Iversen TZ, Hietanen S, Fokdal L, Dahlstrand H, Bjørge L, Birrer MJ, Mirza MR, Rossing M.
Kjeldsen MK, et al. Among authors: werner tl.
Cancer Res Commun. 2024 Dec 1;4(12):3190-3200. doi: 10.1158/2767-9764.CRC-24-0294.
Cancer Res Commun. 2024.
PMID: 39591206
Free PMC article.